PgX Mini

Right drug. Right dose. Right for you.

Connect with our experts

To Book a test

call : +91 75691 32891

What is a PGx Mini panel?

OneDNA PGx Mini is a custom, specialty focused pharmacogenomics panel designed to deliver deeper insights within specific therapeutic areas. Unlike Pharmagenecare, which provides a broad overview across multiple domains, PGx Mini emphasizes a higher number of clinically relevant drugs within each specialty, enabling more precise and actionable guidance. It analyzes your genetic makeup to predict drug response, helping clinicians optimize therapy, minimize adverse effects, and improve treatment outcomes in a targeted, specialty driven approach.

PGx Neuro-Psychiatry Panel

  • Analyses key gene drug interactions to personalise treatment in neurological and psychiatric conditions. By analysing clinically relevant genetic variants such as CYP2D6, CYP2C19, SLC6A4, and COMT this panel guides the optimised use of antidepressants, antipsychotics, mood stabilisers, and anxiolytics.
  • It enables safer, more effective, and individualised care by informing drug selection, dosing strategies, and reducing the risk of adverse drug reactions and treatment resistance.

PGx Cardiology Panel

Evaluates key gene drug interactions to personalise cardiovascular therapy. By analysing clinically relevant genetic variants such as CYP2C19, SLCO1B1, VKORC1, and CYP2C9 this panel supports the optimised use of antiplatelets, statins, betablockers, and anticoagulants. It enables safer, more effective, and individualised treatment by guiding drug selection, improving dosing accuracy, and minimising the risk of adverse drug reactions.

PGx Gastroenterology Panel

Assesses clinically significant gene drug interactions to optimise treatment strategies for gastrointestinal conditions. By analysing key genetic variants in genes such as NUDT15, TPMT, CYP2C19, and DPYD, the panel supports safe prescribing of thiopurines (azathioprine, mercaptopurine), PPIs (omeprazole, pantoprazole), and other commonly used GI medications. This enables clinicians to personalise therapy, avoid dose-related toxicities like leukopenia or hepatotoxicity, and improve treatment outcomes in disorders such as IBD, GERD, and liver related conditions.

PGx Oncology Panel

Evaluates clinically relevant variants in genes such as DPYD, UGT1A1, TPMT, CYP2D6, and GSTP1 to guide safer and more cancer treatment. This panel supports personalised prescribing of chemotherapy agents including 5-FU, irinotecan, thiopurines, tamoxifen, and platinum compounds. It helps identify patients at risk of severe toxicities or suboptimal responses, enabling oncologists to tailor drug choice and dosing to each patient’s genetic profile improving therapeutic outcomes while minimising adverse effects.

Who can consider testing?

1. Patients who are newly diagnosed and about to start medication for the first time. 2. Patients who have tried multiple medications but seen little or no improvement. 3. Patients experiencing unexpected or severe side effects from their current medications. 4. Cancer, cardiac, psychiatric, and GI patients requiring genetically guided personalised therapy. 5. Individuals with depression, anxiety, schizophrenia, or bipolar disorder seeking safer and more effective psychiatric medication choices.

Technique

The test utilizes Allele specific PCR, a highly sensitive molecular technique designed to selectively amplify and detect known genetic variants.

Platform

Conducted using a Multiplex PCR assay, enabling simultaneous analysis of multiple genetic variants in a single reaction.

Variant Type

Focused analysis of Single Nucleotide Polymorphisms (SNPs) that are known to influence pharmacogenomic responses, including drug metabolism, efficacy, and risk of adverse effects.

Accuracy

Delivers up to 99.6% accuracy for clinically classified genes, ensuring reliable and reproducible results to support clinical decision making.

Sample Type

Requires a non-invasive saliva sample, making the test convenient, patient friendly, and easy to collect without the need for blood draws.

Clinical Alignment

Interpretation and reporting are aligned with internationally recognized guidelines, including CPIC (Clinical Pharmacogenetics Implementation Consortium), US FDA pharmacogenomic recommendations, and PharmGKB, ensuring clinically actionable and evidence based insights.

Connect with our expert

Why choose OneDNA

Comprehensive Coverage

Comprehensive testing across both molecular and cytogenetic platforms

Accredited Laboratories

NABL & CAP accredited lab

Support & Care

End-to-end support including genetic counselling and report guidance.

Early & Accurate

High accuracy with advanced technologies and stringent quality controls

Get our brochure

Download now

Frequently Asked Questions

Some Blogs from us

Our Companies

Screens for 90+ conditions

Get in touch

Have questions or need assistance? Get in touch with our team—we’re here to help.

Fill out the form below to get instant access to the product brochure.